Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Treating severe bruxism with botulinum toxin.

E K Tan1, J Jankovic

  • 1Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA.

Journal of the American Dental Association (1939)
|February 19, 2000
PubMed
Summary

Botulinum toxin type A (BTX A) injections effectively treated severe bruxism in 18 patients refractory to conventional therapies. This study suggests BTX A is a safe and effective treatment option for severe bruxism.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tardive dyskinesia versus tardive syndrome. What is in a name?

Parkinsonism & related disorders·2025
Same author

Assessment of social isolation and changes in Parkinson's disease symptoms during the COVID-19 pandemic: A longitudinal study.

Clinical parkinsonism & related disorders·2025
Same author

The Conundrum of Dystonia in Essential Tremor Patients: How does One Classify these Cases?

Tremor and other hyperkinetic movements (New York, N.Y.)·2022
Same author

Mental Illness in the Orang Asli (Aborigines) of West Malaysia.

The Medical journal of Malaysia·2022
Same author

Eosinophilic granulomatosis with polyangiitis after COVID-19 vaccination.

QJM : monthly journal of the Association of Physicians·2021
Same author

Psychological impact of isolation due to COVID-19 among young and fit dormitory residents.

Psychological medicine·2020

Area of Science:

  • Neurology
  • Otolaryngology
  • Dentistry

Background:

  • Botulinum toxin (BTX) is a recognized treatment for movement disorders.
  • The efficacy of BTX for bruxism remains under-investigated.
  • Severe bruxism significantly impacts patients' quality of life.

Observation:

  • Eighteen subjects with severe bruxism, refractory to prior treatments, were enrolled.
  • Botulinum toxin type A (BTX A) was administered to the masseter muscles.
  • The mean duration of symptoms was 14.8 years, with significant tooth wear and functional difficulties.

Findings:

  • BTX A treatment resulted in a mean response duration of 19.1 weeks.
  • The mean peak effect score was 3.4 out of 4, indicating substantial reduction in teeth grinding.
  • Only one patient (5.6%) reported dysphagia as a side effect.

Implications:

  • BTX A is a safe and effective treatment for severe bruxism, especially when conventional therapies fail.
  • Skilled administration by practitioners is crucial for optimal outcomes.
  • Further placebo-controlled studies are warranted to confirm BTX A's therapeutic potential in bruxism.

Related Experiment Videos